Chargement en cours...
The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity
Although the recently concluded CLEOPATRA trial showed clinical benefits of combining trastuzumab and pertuzumab for treating HER2-positive metastatic breast cancer, trastuzumab monotherapy is still the mainstay in adjuvant settings. Since trastuzumab resistance occurs in over half of these cancers,...
Enregistré dans:
| Publié dans: | MAbs |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5058622/ https://ncbi.nlm.nih.gov/pubmed/27380003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2016.1204503 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|